Pierre-Francois Migeotte, HeartKinetics - AI-Based Predictive Technology | LSI Europe '22

Transcription

Pierre-Francois Migeotte  0:03  

Nice introduction. And I'm very happy to be here, just to provide you an overview of hEart kinetics. Our story started 20 years ago with the support of NASA and European Space Agency for the monitoring of cardiac function of astronauts, actually, I'm a feat physicist PhD in space physiology. And I'm also the inventor of the technology at the core of HeartKinetics. And we discovered that astronauts in space do have the same problem as patients here on Earth, they need to extremely easy to use solutions in order to get a very accurate cardiac monitoring. So what we address his heart failure a big problem all over the year, the world 60 million patients, 6 million patients in the US 1 million new patients every year. That's a big problem. And we all know that the main problem is with the diagnostic of heart failure, which is a difficult task, requiring several steps starting from a blood draw an electrocardiogram and chest X ray ended up with an echocardiography. This takes time and money and, most importantly, staff experienced staff to produce these echocardiography. So the result is that heart failure patients are diagnosed too late. It's up to 40% of these patients that have dramatic structural damage to the heart, they will never recover. They become then chronic patients and these chronic patients on boarded into remote monitoring programs, which are using devices that are not specific to heart failure, even the smartwatch is only providing you heart rhythm information, nothing about the cardiac mechanics, which is at stake here, with heart failure. Some of the patients are eligible for invasive solutions like the CardioMEMS from above, but these solutions are costly. And then the limited limited to really the end stage of the pathology. Result is that also 50% of these patients are readmitted within six months. It's too early, and it cost a huge amount to healthcare systems in the society. The financial burden of heart failure is expected to double by the end of the decade if we do nothing. And so we ask ourselves, what can we do with our space technology, we think we have a solution for those two problem screening and monitoring of heart failure and then be able to intercept the problems on time. It may sound crazy, but yes, only a smartphone application can do this. And we are using smartphone motion sensors, which are accelerometers and gyroscopes, the ones that are used to count your steps, you may scan the code and download the app and use LSI as a patient code to test our solution. It's already available still in clinical trial. What we do provide is, let's say on the spot measurements, when you place the smartphone on your chest for one minute, we capture vibration from the chest that are caused by injection of blood and emotion of blood into the main arteries. And with this, and with our proprietary AI cloud computing infrastructure, we provide a risk score of heart failure. How does it work, it's just like having an intelligent stethoscope in your pocket. So a solution that most of the doctors are used to make use of it and what is unique is that we patented the way we calibrate the vibration into kinetic energy in the different phases of the cardiac cycle. So what we demonstrated in several high ranking publication is that we have a good correlation with ejection fraction cardiac output stroke volume, maximum peak flow velocity, very important for adoption by the cardiologist. Several publication that the last one here is a proof of concept of large scale clinical trial. What you can see in green is normal I would say this unique patients with without heart failure, arriving at the emergency department dyspnea is a sign that should elicit a series of action to let's say, identify heart failure patients or solution here in 65 patients is already very be accurate in differentiating these patients and that's only with a single parameter. But if we train our AI model on 350 patients, this is what we can achieve a higher number of sensitivity, specificity and accuracy than the standard of cost of care, which is a blood test. Recently, we had a retrospective analysis on five years old clinical trial, and we could see and demonstrate, and that's very important. Not all solution is more predictive of the fatal outcome than echocardiography can be. You see here a high statistical significance to separate patients who died early with low kinetic energy than those who had the better expectancy or market value proposition is to offer the solution as a screening tool. The potential is huge, there are hundreds of millions of patients at risk of heart failure in the US only. We will start with screening at the emergency department. It's over 17 million visits each year in this department, so it makes a 2.5 billion market opportunity. A value proposition is to sell the solution as monthly patient licenses to hospitals, so that they can improve the referrals of the right patients in the cardiology in order to save them time and money and provide these patients with more invasive solutions. So this is our three hour solution for the emergency department. Our solution is unique in the way it's extremely fast, extremely easy to use. It doesn't require any investment, it allows early detection. And we have the ambition to provide also remote monitoring at the discharge of the hospital, which may prevent some of the real specialization of these patients. Very important to the field of hospitals. We have a leadership team ready to operate. We are now 20 in the company, and we are scaling it so we on boarded a top notch international advisory board with a very well known and famous key opinion leader such as Professor David Butler here. And we have further landscape of key opinion leaders and PIs that are ready to operate a clinical trial on 1000 patients in Europe and in the US. Our roadmap is to further or clinical trials validation in Europe get CE mark in mid next year, and then access to FDA validation in 24 to enter the market. We are raising today pre series A between 10 and 15 million. These will be complemented by non dilutive funding based on grants from the European Union. So I thank you for your attention. If you want to reach me with questions don't hesitate. If you want to test the application also, I invite you to scan this QR code and enter the VLSI patient code. Thank you very much for for your attention.